609A / 3SBio - LARVOL DELTA

A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties. (PubMed, MAbs) - "In this study, we identified an anti-PD1 monoclonal antibody, 609A, whose heavy chain can pair with a variety of light chains from different antibodies while maintaining its PD1 binding/blocking activity...Importantly, the BsAbs demonstrated the desired IgG-like physicochemical properties in terms of high-level expression, ease of purification to homogeneity, good stability and in vivo pharmacokinetics. In summary, we describe a novel and flexible plug-and-play platform to engineer IgG-like BsAbs with excellent development potential for clinical applications."

IO biomarker • Journal • Immune Modulation • Inflammation • Oncology

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma (clinicaltrials.gov) - P2; N=30; Not yet recruiting; Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Clinical • New P2 trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • MRI

A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma (clinicaltrials.gov) - P2; N=70; Not yet recruiting; Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Clinical • New P2 trial • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor